Opinion

Video

Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR Agents

Author(s):

Angeles Alvarez Secord, MD, MHSc ,Dana M. Chase, MD, FACOG

Panelists discuss recent data on emerging antibody-drug conjugates in advanced and recurrent endometrial cancer, including anti-TROP2 agents like sacituzumab govitecan from the TROPiCS-03 trial, datopotamab deruxtecan from TROPION-PanTumor03, and sacituzumab tirumotecan, as well as anti–folate receptor agents like luveltamab tazevibulin and rinatabart sesutecan, while offering future perspectives and closing thoughts on the evolving role of these agents in the treatment landscape for endometrial cancer.

Video content above is prompted by the following:

  • Briefly comment on recent data surrounding other antibody-drug conjugates (ADCs) in advanced/recurrent endometrial cancer and discuss the evolving role of these agents in the treatment landscape.
  • Anti-TROP2 ADCs
  • Sacituzumab govitecan – TROPiCS-03
  • Datopotamab deruxtecan – TROPION-PanTumor03
  • Sacituzumab tirumotecan
  • Anti-FR ADCs
  • Luveltamab tazevibulin – STRO-002-GM1
  • Rinatabart sesutecan
  • Please share future perspectives and closing thoughts on the treatment of endometrial cancer.
Related Videos
5 KOLs are featured in this series.
5 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment